MEI Pharma Announces 1-for-20 Reverse Stock Split
MEI Pharma, Inc. (Nasdaq: MEIP) has announced a 1-for-20 reverse stock split, effective from April 17, 2023. This decision, approved by stockholders on January 5, 2023, aims to increase the per share trading price and meet Nasdaq's minimum bid price requirement for continued listing.
The split will reduce the number of outstanding shares from approximately 133.3 million to around 6.7 million. Fractional shares will not be issued; affected stockholders will receive cash equivalent to their fractional shares based on the closing price on April 14, 2023.
Computershare Trust Company will manage the transfer process. Changes to the CUSIP number will also take effect on the same date.
- Approval of a reverse stock split may help MEI Pharma comply with Nasdaq's minimum bid price requirement.
- The reduction in outstanding shares could potentially enhance stock value per share.
- The need for a reverse stock split indicates potential struggles to maintain stock price compliance on Nasdaq.
- Such actions can often be perceived negatively by investors due to dilution concerns and market instability.
The 1-for-20 reverse stock split will automatically convert 20 current shares of MEI’s common stock into one new share of common stock. No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise hold a fractional share of MEI’s common stock will receive a cash payment in lieu thereof, at a price equal to the fraction to which the stockholder would otherwise be entitled, multiplied by the closing price of MEI’s common stock on Nasdaq on
In connection with the reverse stock split, the Company's CUSIP number will change to 55279B301 on
About
Forward-Looking Statements
Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including our expectations regarding the effect of the reverse stock split, our ability to meet the minimum bid price requirement, our ability to regain compliance with the Nasdaq continued listing requirements, and our financial condition, growth and strategies. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to our ability to regain compliance with Nasdaq’s minimum bid price requirement, or otherwise maintain compliance with any other listing requirements on Nasdaq, the potential de-listing of our shares on Nasdaq, our strategy, business plans and focus, and the other risks set forth in our filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20230414005026/en/
Tel: 858-369-7104
investor@meipharma.com
Source:
FAQ
What is the significance of the reverse stock split for MEI Pharma (MEIP)?
When will the MEI Pharma (MEIP) stock split take effect?
How will the reverse stock split impact MEI Pharma's outstanding shares?
What should MEI Pharma shareholders expect during the reverse stock split?